Arena plumpness tablet wins over U.S. advisers

<p>SILVER SPRING, Maryland (Reuters) An initial obesity tablet from Arena Pharmaceuticals Inc won a support of U.S. advisers on Thursday, as open health advocates pull for new solutions to a nations flourishing plumpness epidemic.
A row of outward experts to a Food and Drug Administration voted 18 to 4 to suggest capitulation of lorcaserin, bringing a drug a step closer to U.S. capitulation as one of a initial new weight-loss treatments in over a decade.
Lorcaserin is Arenas many critical product.
Shares of Arena, that were halted tentative a row vote, scarcely doubled in value to $6.92 after shutting during $3.66 on Wednesday.
Arenas tablet is one of 3 new intensity plumpness treatments opposed to benefit U.S. capitulation and be a initial new weight-loss diagnosis on a marketplace after initial rejections over reserve issues.
The FDA initial deserted lorcaserin, that is being grown in partnership with Japane...